Bethany Medical Center
Bethany Medical Center was paid $1.70M by Medicaid between Jul 2019 and Dec 2024, across 72 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 35% of everything it billed.
GREENSBORO, NC 27410
Next to other Dermatology Physician providers in North Carolina
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 134 | $7K | |
| 2020 | 1,882 | $42K | |
| 2021 | 9,500 | $157K | |
| 2022 | 23,870 | $365K | |
| 2023 | 33,521 | $481K | |
| 2024incomplete | 50,394 | $648K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 35% | 9,561 | 7,050 | $592K |
| 99199 | Unlisted special service, procedure or report | 21% | 58,089 | 37,574 | $355K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.7% | 1,781 | 1,495 | $114K |
| 83970 | 6.6% | 2,482 | 2,106 | $112K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.8% | 2,510 | 2,138 | $81K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.7% | 1,965 | 1,606 | $81K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 1.9% | 319 | 273 | $32K |
| 80061 | Lipid panel | 1.9% | 2,312 | 1,960 | $32K |
| 94375 | 1.6% | 1,313 | 1,070 | $28K | |
| 86769 | 1.2% | 546 | 437 | $20K | |
| 84480 | 1.1% | 1,312 | 1,095 | $19K | |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.1% | 217 | 168 | $18K |
60 more codes
| 80053 | Comprehensive metabolic panel | <1% | 1,831 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,689 | $16K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,636 | $13K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 150 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 192 | $13K |
| 84439 | <1% | 1,313 | $12K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 650 | $12K |
| 99406 | <1% | 1,514 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,677 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 319 | $10K |
| 99443 | <1% | 167 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 124 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 514 | $8K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 132 | $8K |
| 81025 | <1% | 1,225 | $7K | |
| 93000 | <1% | 637 | $7K | |
| 86703 | <1% | 442 | $6K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 53 | $5K |
| 86803 | <1% | 272 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 195 | $4K |
| 87340 | <1% | 396 | $4K | |
| 80050 | General health panel | <1% | 379 | $4K |
| 81002 | <1% | 1,455 | $2K | |
| 82728 | <1% | 95 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 106 | $1K |
| 99385 | <1% | 13 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $1K |
| 83550 | <1% | 96 | $964.05 | |
| 82607 | <1% | 50 | $885.24 | |
| 82746 | <1% | 50 | $863.31 | |
| 99442 | <1% | 21 | $858.62 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $645.12 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14 | $605.46 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 341 | $568.39 |
| 82962 | <1% | 414 | $519.65 | |
| 87905 | <1% | 31 | $461.75 | |
| 83540 | <1% | 44 | $320.04 | |
| 90688 | <1% | 19 | $142.80 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16 | $97.79 |
| 3074F | <1% | 3,170 | $9.68 | |
| 3048F | <1% | 419 | $9.68 | |
| 3078F | <1% | 2,766 | $9.67 | |
| 3044F | <1% | 854 | $9.67 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 75 | $2.47 |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 100 | $1.14 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 96 | $0.03 |
| 4004F | 0% | 964 | $0.00 | |
| 3077F | 0% | 229 | $0.00 | |
| 1159F | 0% | 47 | $0.00 | |
| 3050F | 0% | 14 | $0.00 | |
| 3288F | 0% | 13 | $0.00 | |
| 3049F | 0% | 220 | $0.00 | |
| 3079F | 0% | 1,103 | $0.00 | |
| 1170F | 0% | 48 | $0.00 | |
| 3008F | 0% | 3,712 | $0.00 | |
| 3075F | 0% | 268 | $0.00 | |
| 3080F | 0% | 123 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 45 | $0.00 |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 0% | 16 | $0.00 |
| 1125F | 0% | 314 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Bethany Medical Center | High Point, NC | $18.31M |
| Bethany Medical Center | Greensboro, NC | $7.28M |
| Bethany Medical Center | Greensboro, NC | $5.72M |
| Bethany Medical Center | Winston Salem, NC | $5.13M |
| Bethany Medical Center | Winston Salem, NC | $4.74M |
| Bethany Medical Center | High Point, NC | $3.77M |
| Bethany Medical Center | Kernersville, NC | $2.29M |
| Bethany Medical Center | Kernersville, NC | $1.62M |
| Bethany Medical Center | Mount Airy, NC | $1.50M |
| Bethany Medical Center, PA | High Point, NC | $1.47M |
| Bethany Medical Center PA | High Point, NC | $1.25M |
| Bethany Medical Center PA | High Point, NC | $1.13M |
| Bethany Medical Center, PA | High Point, NC | $645K |
| Bethany Medical Center | High Point, NC | $524K |
| LJP Anesthesia Services, PLLC | High Point, NC | $198K |
| Bethany Medical Center | High Point, NC | $88K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.